

May 26, 2017



DCAT
TOP ↑
Industry
NEWS

***BUSY WEEK?** Here are the
TOP INDUSTRY NEWS stories
you might have missed, as
selected by DCAT Editorial
Director Patricia Van Arnum.*

More successful NDA approvals
than any other. Delivered.



Patheon
A HEALTHIER WORLD. DELIVERED.

1. [Novartis to Add 350 Positions in Biologics and Cut 500 Other Positions](#)

Novartis plans to add 350 new positions for biological development and manufacturing in Switzerland while cutting approximately 500 positions in traditional production, coordination, and development areas in Switzerland over the next 18 months. The move is part of the company's ongoing transformation into an integrated business model. [Read More](#)

2. [EMA Advisory Committee Recommends Sanofi's Biosimilar of Insulin Lispro](#)

An advisory committee of the European Medicines Agency has adopted a positive opinion for the marketing authorization of a biosimilar by Sanofi for insulin lispro, marking Sanofi's first major regulatory milestone for a biosimilar diabetes treatment. The news is part of *DCAT Value Chain Insights Pipeline News*. [Read More](#)

3. [AstraZeneca Sells European Rights to Cardio Drugs to for \\$300 Million](#)

AstraZeneca has agreed to sell to Recordati S.p.A, an Italian pharmaceutical company, the commercial rights to two beta-blocker drugs for the control of hypertension, angina, and heart failure. AstraZeneca will manufacture and supply the drugs. [Read More](#)

4. [Granules India Plans \\$35 Million Expansion in the US](#)

Granules India Ltd., a manufacturer of active ingredients, preformulation ingredients, and finished dosage forms, plans to invest \$35 million to expand its pharmaceutical R&D and manufacturing capabilities in Fairfax County, Virginia. [Read More](#)

5. [KBI Biopharma Plans \\$30 Million Biomanufacturing Expansion](#)

KBI Biopharma (KBI), a contract biologics manufacturer, is investing \$30 million to expand its biopharmaceutical manufacturing capacity at its facilities in Durham, North Carolina and Boulder, Colorado to include additional cell-culture commercial capacity and smaller scale fermentation capacity. [Read More](#)

6. [Sun Pharma Receives FDA Complete Response Letter for Manufacturing Issues](#)

Sun Pharma Advanced Research Company Limited, part of Sun Pharmaceutical Industries, has received a Complete Response Letter from the FDA regarding manufacturing issues at Sun Pharma's

Halo, India manufacturing facility.. [Read More](#)

7. [President Trump's Proposed Budget Sets Up Battle in User Fees, Funding](#)

President Donald Trump's FY 2018 budget proposal for the FDA, released this week, sets up a battle with Congress as the proposal seeks to reduce funding for the FDA while further increasing industry user fees and also reduces science-based research funding. [Read More](#)

8. [In a First, FDA Approves Merck & Co.'s Biomarker for Cancer](#)

Reflecting the changing nature of drug development to precision medicines, the FDA has approved a biomarker for Merck & Co's immuno-oncology drug, Keytruda, marking the first FDA approval for a drug based on a tumor's biomarker without regard to the tumor's original location in the body. [Read More](#)

9. [GSK Recalls Additional Respiratory Drug Inhalers](#)

GlaxoSmithKline (GSK) has issued a voluntary Class II recall of 562,883 inhalers of Ventolin HFA (albuterol sulfate) inhalation aerosol due to a defective delivery system that resulted in an elevated number of units with out-of-specification results for a leak rate. The recall is in addition to a nearly 600,000-unit recall made by the company in March 2017. [Read More](#)

10. [New GSK CEO Targets Pharmaceutical Growth](#)

Emma Walmsley, who became CEO of GlaxoSmithKline (GSK) on April 1, is seeking better returns from new product sales in pharmaceuticals and vaccines with a goal to boost revenues in this area by £6 billion (\$7.8 billion) by 2018. [Read More](#)

***The DCAT organization is happy to provide this service to its members each Friday.
Have a great weekend!***

About Top Industry News

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



One Union Street, Suite 208, Robbinsville, NJ 08691
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599
www.dcat.org

Drug, Chemical, & Associated Technologies Association, One Union Street,
Suite 208, Robbinsville, NJ 08691

[SafeUnsubscribe™ {recipient's email}](#)

[Forward this email](#) | [Update Profile](#) | [About our service provider](#)

Sent by mailmanager@dcad.org